Mirati Therapeutics is a clinical-stage oncology company developing therapeutics to address the genetic and immunological promoters of cancer. Co.'s product candidates include: Adagrasib, an investigational, selective, specific, potent and orally available KRAS G12C inhibitor in clinical development as a monotherapy and in combination with other agents; MRTX1133, an investigational, selective, specific and potent KRAS G12D inhibitor in preclinical development; Sitravatinib, an investigational spectrum-selective kinase inhibitor; and MRTX1719, an internally discovered investigational synthetic lethal PRMT5 inhibitor to target the PRMT5/methylthioadensoine complex in preclinical development. We show 44 historical shares outstanding datapoints in our coverage of MRTX's shares outstanding history.
Understanding the changing numbers of MRTX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like MRTX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching MRTX by allowing them to research MRTX shares outstanding history
as well as any other stock in our coverage universe. |
Free MRTX Email Alerts:
Video: Shares Outstanding Importance
